Alice Guyon

Research Director in CNRS



06 18 72 11 00





IPMC, UMR 7275

660 route des Lucioles

06560 Valbonne Sophia Antipolis


Birth date:


  • White LinkedIn Icon
  • White Facebook Icon
  • White Instagram Icon
Couverture livre EE.png

Welcome to my website!


My name is Alice Guyon. I am Director of Research at the CNRS, at the Institute of Molecular and Cellular Pharmacology (IPMC). My research focuses on Neuroscience and interactions between the nervous, endocrine and immune systems under physiological and pathological conditions.      

 Recently, I focused in integrative medicine practices and I try to develop innovative approaches to evaluate these practices and try to understand their physiological mechanisms.


Qualification to o the function of Professeur


Habilitation to Direct Research

Université Paris VI, Neurosciences


PhD from Université Paris VI in Neurosciences,

Defense: 7 Janvier 1995.

Mention "Très Honorable avec Félicitations du Jury"


DEA of Neurosciences from Université Paris VI

              Magister of Biology from Université Paris VI


Master of Biology and Physiology from Université Paris VI


Licence in Cellular Biology and Biochemistry. Université Paris VI


Ecole Normale Supérieure de Paris (Rue d’Ulm), section Biology

Driving Licence

BAFA (Leader formation)

AFPS (First Aid formation)

Autorisation to experiment on animals

Langages : French, English, Spanish


Institut de Pharmacologie Moléculaire et Cellulaire-

Equipe de Gérard Lambeau

Reconversion thématique : études scientifiques cliniques des effets d’approches complémentaires


Directeur de Recherches (DR2) à l’IPMC-CNRS UMR 7275


Chargée de recherches (CR1) à l’IPMC-CNRS UMR 7275, Développement d’une équipe Joëlle Chabry et Agnès Petit (en co-direction) au sein du groupe de Catherine Heurteaux 


 Mission à UC Berkeley USA dans le laboratoire du Pr Isacoff


Délégation (2001-2004), Chargée de recherches 2ème classe (CR2,  2004) puis première classe (CR1, 2009) au CNRS dans l’équipe dirigée par le Dr Jean-Louis Nahon à l’IPMC (CNRS UMR 6097 dirigé par le Dr. P. Barbry).


Maître de conférences (Amiens, ESPCI, Université Pierre et Marie Curie, Paris)

Team GL sans blouse.jpg
Team GL sans blouse.jpg

Institute of Pharmacology, Molecular and Cellular

Team of Gérard Lambeau

Clinic studies of complementary approaches in health

Research Director (DR2) in IPMC-CNRS UMR 7275


Researcher (CR1) in IPMC-CNRS UMR 7275,

Creation of a team with Joëlle Chabry and Agnès Petit (co-direction) in the group of Catherine Heurteaux 

 Mission in UC Berkeley USA in the laboratory of Pr Isacoff


Délégation (2001-2004), researcher(CR2,  2004) then (CR1, 2009) in CNRS in the team directed byJean-Louis Nahon in IPMC (CNRS UMR 6097 directed by P. Barbry).


Assistant Professor (Amiens, ESPCI, Université Pierre et Marie Curie, Paris)


Ecole Normale Supérieure of Paris

 Allocataire Moniteur Normalien


During my career, I studied the modulation of the excitability of several neuronal populations by different pharmacological substances in the context of several pathologies such as absence-type epilepsy, Parkinson's disease, eating disorders or the Depression. I participated in the illumination of the mechanisms of action of ethosuximide (an anti-absence of which I helped to understand the target channels), furosemide (a diuretic that also acts on GABAA receptors) and recently, I have shown that baclofen, in addition to its action on GABAB receptors, also acts on a chemokine receptor, CXCR4.       

An important part of my work has been to demonstrate the major role played by chemokines, chemoattractant cytokines, in regulating the electrical activity of neurons in many areas of the brain.       

Finally, an original part of my work has been to show that the ciliary beeting frequency of cilia lining te cerebral ventricules is modulated by neurotransmitters and metabolites.

Figure 12 Livre EE.jpg
MCH et cils.jpg

Since 2012, I have developed with Joëlle Chabry and Agnès Petit a theme about the beneficial effects of environmental enrichment in the treatment of depression, in the team of Catherine Heurteaux at the IPMC.

I became interested in the more neuro-immunological aspects of this project by studying more precisely the role of microglia and T cells in the antidepressant effects of environmental enrichment. This project allowed me to use both my knowledge of neuro-immunology and my skills in electrophysiology, and I benefited from all the techniques available in the laboratory. For this project, I have also established numerous collaborations within the IPMC with notably Nicolas Glaichenhaus's teams (immunologist) but also outside the IPMC in France and abroad.

      Depression is accompanied by structural and neurochemical changes in the brain, particularly within the limbic system, in particular the hippocampus, including a decrease in its overall volume, a reduction in neurogenesis and synaptogenesis, and synaptic plasticity. There are also changes in the activity of mono-aminergic systems, particularly serotoninergic in the Raphé nuclei, dysregulation of the hypothalamic-pituitary-adrenal axis and neuroinflammation. The classical treatments for depression rely mainly on the modulation of mono-aminergic neurotransmission systems, but these treatments have limitations and disadvantages, in particular a long delay in action and resistance to treatment in many patients.

      In addition to the pharmacological approach, another strategy to combat depression in humans is the use of behavioral therapies: increased physical activity, sensory stimulation and social interaction would have beneficial effects in patients depressive. In mice, the enriched environment model that is to say stimulant without being stressful, limits the anxio-depressive syndromes induced for example by prolonged treatment with corticosterone, the stress hormone in mice. Depression is accompanied by neuroinflammation. Different cell populations contribute to inflammation of the central nervous system, including resident immune cells of the brain (microglia and perivascular macrophages) and infiltrating immune cells (inflammatory and neutrophilic monocytes). The cytokines produced by these cells can by altering the activity of the neural networks lead to a depressive state.


      In the first part of our work, we have shown that one of the mediators of the beneficial effects of EE is an adipokine (hormone produced by adipose tissue), adiponectin, which by its anti-inflammatory effects on microglia and resident macrophages has beneficial effects on the depressive anxiety behavior of mice. We have shown the antidepressant properties of an adiponectin receptor agonist called adiporon, for which we have filed a patent.       We went further by developing the novel idea that T cells also might play a role in depression, but a beneficial role in promoting plasticity and we investigated the mechanisms by which CD8 + and CD4 + T cells selectively affect the brain plasticity.

Figure 6 Livre EE.jpg

Enrichissement de l'environnement chez la souris

As a continuation of this work, since 2018 I have begun a thematic reconversion to scientifically study the clinical effects of several unconventional and complementary approaches. Indeed, for reasons of personal ethics, I decided to stop animal testing and turn to clinical studies.    


In 2018, I joined Gérard Lambeau's team at IPMC. This team specializes in phospholipases A2 and their receptors. These enzymes have a key role in inflammation by releasing inflammatory phospholipids that act in parallel with cytokines, which particularly interested me. This role has been little explored at the cerebral level in the context of neuroinflammation. In addition, this team has already started several collaborative clinical studies.       


My intention is to set up a mobile experimental laboratory able to evaluate different unconventional and complementary approaches, on the basis of physiological measurements (heart rate, respiratory rate, blood pressure, SpO2, electroencephalogram, electrodermal conductance, blood measurements of cortisol, cytokine and inflammatory PLA2 levels, etc.) and psychological levels (questionnaires, attention tests, posture, voice and facial analysis, etc.).

In order to train me in these new techniques for me, I did a training in good clinical research practices at the Clinical Research and Innovation Department (DRCI) of Nice and I followed the ED of Meditation and Mindfulness, integrated health approach organized by Antoine Lutz in Lyon in 2019. I also integrated the Observatory for Complementary and Non-Conventional Medicine in Nice (OMCNC) in 2018.   


 Currently, I am developing several projects in parallel, which are described in the "Integrative Health" tab.

Interactions between nervous, endocrine and immune system in link with environment

Figure 8 Livre EE.jpg

Recordings with microelectrodes and Patch–Clamp (whole cell and single cell), in vitro (acute and organoitypic brain sclices, acutely dissociates and cultured cells) and in  Xenopus oocytes


pClamp, Axograph, Acquis I, Matlab, Xcell, Prism, Sigmaplot, Canvas, Powerpoint, Illustrator, Photoshop


Calcium imaging with FURA, TIRF microscopy (total internal reflection fluorescence), photoswitch

Molecular Biology

 DNA and RNA extraction, PCR, single cell RT-PCR

Protein expression

in Xenopus oocytes, HEK cells and organotypic slices (lipofectamine, Gene-gun and virus)

Clinical Research


Assistant Professor

(Amiens, Paris 6, ESPCI)

Teaching Neurophysiology

Practicals in animal physiology

and electrophysiology

192 UC/year



Teaching in Ecole Polytechnique Universitaire (12h), Neurophysiology (Parkinson disease, feeding behavior disorders, Neuro-immunology)


Teaching in University of Nice Sophia Antipolis (6 h) New strategies to treat depression. Master II UE « Endocrinologie moléculaire et pathologies »,)

Teaching in Master of Science

MOD4NEUCOG (18h) Neurophysiology

Nervous system, sensori-motricity,

breain plasticity, neuro-immunology

Interactions between gut microbiota and the brain



January -June 2020  Mini-projets of MSC (Master of Science) MOD4NEUCOG (Modelisation for Neurosciences and Cognition, Université Côte d'Azur) of Mathieu Marconi, Master 1  CognitivesSciences  of Elisa Elleuch. MSC MOD4NEUCOG M2 personal project of Kiribel Danieli.

October- Décember 2019  MSC MOD4NEUCOG M2 training of Norma Gomes and Sepideh Iranfar.


April-Mai 2019 Mini-projects of MSC of Norma Gomes and Safia Mensor,personnal project of  MSC of Norma Gomes, Sepideh Iranfar and Julien Moreira.


Janvier 2014- 2017    M2 then PhD of  M Hadi Zarif. M2 pthen PhD of Sarah Nicolas, DUT training of Maud Maillot and M1 training of Valentine Golzne.

Summer 2014       Summer training of Fabienne Massa

February-August 2013   M2 training of Salma Hosseiny, BTS of Vérane Peyratout.  M1 of Mariel Pietri.


February-August 2012     M1 of Salma Hosseiny.

April-July 2010  M2 « Computational Biology » of Ecole Polytechnique Universitaire (EPU), M. Navean Ramkumar.


January-March 2010    BTS, Priscilla Maitre.

2009-2013    Post doctorate of Grégory Conductier,BTS of Raphaël Chapot, summer training of Thomas Boser, DUT of Thibault Lemaire.

1992-2002     DEA of Stéphanie Laurent, PhD of Elisabeth Bugnard